title: A comparison between use of spray and freeze drying techniques for preparation of solid self-microemulsifying formulation of valsartan and in vitro and in vivo evaluation.
abstract: The objective of the present study was to develop self micro emulsifying formulation (SMEF) of valsartan to improve its oral bioavailability. The formulations were screened on the basis of solubility, stability, emulsification efficiency, particle size and zeta potential. The optimized liquid SMEF contains valsartan (20% w/w), Capmul MCM C8 (16% w/w), Tween 80 (42.66% w/w) and PEG 400 (21.33% w/w) as drug, oil, surfactant and co-surfactant, respectively. Further, Liquid SMEF was adsorbed on Aerosol 200 by spray and freeze drying methods in the ratio of 2 : 1 and transformed into free flowing powder. Both the optimized liquid and solid SMEF had the particle size <200 nm with rapid reconstitution properties. Both drying methods are equally capable for producing stable solid SMEF and immediate release of drug in in vitro and in vivo conditions. However, the solid SMEF produced by spray drying method showed high flowability and compressibility. The solid state characterization employing the FTIR, DSC and XRD studies indicated insignificant interaction of drug with lipid and adsorbed excipient. The relative bioavailability of solid SMEF was approximately 1.5 to 3.0 folds higher than marketed formulation and pure drug. Thus, the developed solid SMEF illustrates an alternative delivery of valsartan as compared to existing formulations with improved bioavailability.
authors: Department of Pharmaceutics, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005, India.
authors: Sanjay Kumar
authors: SK
authors: Singh
authors: Parameswara Rao
authors: PR
authors: Vuddanda
authors: Sanjay
authors: S
authors: Singh
authors: Anand Kumar
authors: AK
authors: Srivastava
mesh_terms: D000284:Administration, Oral; D000818:Animals; D003890:Desiccation / Q000379:methods*; D004339:Drug Compounding / Q000379:methods*; D004655:Emulsions / Q000008:administration & dosage / Q000138:chemical synthesis; D005612:Freeze Drying / Q000379:methods*; D005740:Gases / Q000737:chemistry*; D008297:Male; D008657:Metabolic Clearance Rate; D010316:Particle Size; D051381:Rats; D017207:Rats, Sprague-Dawley; D012995:Solubility; D013777:Tetrazoles / Q000008:administration & dosage / Q000138:chemical synthesis* / Q000493:pharmacokinetics*; D014633:Valine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000493:pharmacokinetics; D000068756:Valsartan
chemical_list: D004655:Emulsions; D005740:Gases; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine
references: Int J Pharm. 2009 Jun 5;374(1-2):66-72
references: 19446761
references: Curr Drug Saf. 2011 Nov 1;6(5):329-38
references: 22424541
references: J Pharm Sci. 2011 Jun;100(6):2366-78
references: 21491449
references: Drug Deliv. 2010 Jul;17(5):322-9
references: 20367177
references: Eur J Pharm Biopharm. 2008 Oct;70(2):439-44
references: 18603415
references: Nanomedicine (Lond). 2008 Jun;3(3):305-19
references: 18510426
references: Eur J Pharm Biopharm. 2000 Jul;50(1):3-12
references: 10840189
references: J Pharmacol Toxicol Methods. 2000 Jul-Aug;44(1):235-49
references: 11274893
references: Drug Dev Ind Pharm. 2000 Jan;26(1):27-34
references: 10677807
references: AAPS J. 2007 Oct 26;9(3):E344-52
references: 18170981
references: PDA J Pharm Sci Technol. 2013 Jan-Feb;67(1):23-34
references: 23385561
references: Am J Health Syst Pharm. 2000 Jul 1;57(13):1231-41
references: 10902066
references: Int J Pharm. 2006 Jun 6;315(1-2):110-21
references: 16563673
references: Drug Dev Ind Pharm. 2005 Sep;31(8):785-94
references: 16221613
references: Eur J Pharm Biopharm. 2006 Jul;63(3):288-94
references: 16527467
references: Pharm Res. 1995 Mar;12(3):413-20
references: 7617530
references: AAPS PharmSciTech. 2010 Mar;11(1):314-21
references: 20182825
references: Eur J Pharm Biopharm. 2003 Nov;56(3):501-5
references: 14602195
references: Int J Pharm. 2010 Jan 4;383(1-2):1-6
references: 19698771
references: Int J Pharm. 2004 Feb 11;270(1-2):109-18
references: 14726127
references: Drug News Perspect. 2003 Jan-Feb;16(1):57-62
references: 12682673
references: Eur J Pharm Sci. 2008 Nov 15;35(4):257-63
references: 18706499
references: Eur J Pharm Sci. 2000 Oct;11 Suppl 2:S93-8
references: 11033431
references: Eur J Pharm Sci. 2001 Dec;14(4):331-7
references: 11684408
references: Pharm Res. 1992 Jan;9(1):87-93
references: 1589415
references: Drug Discov Today. 2008 Jul;13(13-14):606-12
references: 18598917
references: Eur J Pharm Biopharm. 2007 May;66(2):227-43
references: 17127045
references: Br J Pharmacol. 1993 Oct;110(2):761-71
references: 8242249
references: Adv Drug Deliv Rev. 2008 Mar 17;60(6):734-46
references: 18045728
references: Eur J Clin Pharmacol. 1997;52(2):115-20
references: 9174680
references: Drug Dev Ind Pharm. 2007 Dec;33(12):1318-26
references: 18097805